Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TARA Stock Forecast 2026-2027
$5.24
Current Price
$280.80M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TARA Price Targets
+472.5%
To High Target of $30.00
+367.6%
To Median Target of $24.50
+300.8%
To Low Target of $21.00
TARA Price Momentum
+2.3%
1 Week Change
-8.1%
1 Month Change
-1.3%
1 Year Change
-1.7%
Year-to-Date Change
-33.0%
From 52W High of $7.82
+89.2%
From 52W Low of $2.77
📊 TOP ANALYST CALLS
Did TARA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ArTara is one of their latest high-conviction picks.
Latest TARA Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, TARA has a bullish consensus with a median price target of $24.50 (ranging from $21.00 to $30.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $5.24, the median forecast implies a 367.6% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Leland Gershell at Oppenheimer, projecting a 472.5% upside. Conversely, the most conservative target is provided by Soumit Roy at Jones Trading, suggesting a 300.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TARA Analyst Ratings
7
Buy
0
Hold
0
Sell
TARA Price Target Range
Low
$21.00
Average
$24.50
High
$30.00
Current: $5.24
Latest TARA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TARA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 7, 2026 | Piper Sandler | Kelsey Goodwin | Overweight | Initiates | $24.00 |
| Dec 3, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Reiterates | $23.00 |
| Nov 19, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Reiterates | $23.00 |
| May 22, 2025 | Jones Trading | Soumit Roy | Buy | Initiates | $21.00 |
| Apr 28, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $23.00 |
| Apr 16, 2025 | Scotiabank | George Farmer | Sector Outperform | Initiates | $12.00 |
| Mar 14, 2025 | Cantor Fitzgerald | Li Watsek | Overweight | Initiates | $N/A |
| Mar 11, 2025 | LifeSci Capital | Outperform | Initiates | $22.00 | |
| Mar 6, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Dec 6, 2024 | Guggenheim | Michael Schmidt | Buy | Reiterates | $20.00 |
| Dec 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Aug 12, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $25.00 |
| Aug 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| May 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Apr 22, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $30.00 |
| Apr 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $23.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Aug 4, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Jul 10, 2023 | Guggenheim | Charles Zhu | Buy | Assumes | $22.00 |
Protara Therapeutics Inc. (TARA) Competitors
The following stocks are similar to ArTara based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Protara Therapeutics Inc. (TARA) Financial Data
Protara Therapeutics Inc. has a market capitalization of $280.80M with a P/E ratio of -2.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -49.4%.
Valuation Metrics
Market Cap
$280.80M
Enterprise Value
$92.86M
P/E Ratio
-2.4x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+65.6%
Current Ratio
13.7x
Debt/Equity
2.8x
ROE
-49.4%
ROA
-31.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Protara Therapeutics Inc. (TARA) Business Model
About Protara Therapeutics Inc.
What They Do
Develops therapies for rare and specialty diseases.
Business Model
Protara Therapeutics focuses on developing innovative treatments for rare diseases and conditions with unmet medical needs. The company generates revenue primarily through the advancement of its drug candidates, such as TARA-002, which is in development for lymphatic malformations and bladder cancer.
Additional Information
Based in New York, Protara is dedicated to addressing significant gaps in treatment options within oncology and rare diseases, making a meaningful impact on patient outcomes and contributing to the advancement of medical research.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
28
CEO
Mr. Jesse Shefferman
Country
United States
IPO Year
2014
Website
www.protaratx.comProtara Therapeutics Inc. (TARA) Latest News & Analysis
Latest News
Quick Summary
Protara Therapeutics (Nasdaq: TARA) received FDA Breakthrough Therapy and Fast Track designations for TARA-002, a cell-based therapy for pediatric lymphatic malformations, enhancing its development prospects.
Why It Matters
FDA designations for TARA-002 enhance Protara's growth potential, signaling faster development and potential market entry, which can drive stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Protara Therapeutics (Nasdaq: TARA) will present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 pm PT, focusing on its cancer and rare disease therapies.
Why It Matters
Protara Therapeutics' presentation at a major healthcare conference could indicate progress in their drug development, potentially impacting stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Protara Therapeutics closed a public offering of 13.04 million shares at $5.75 each, raising about $75 million. Proceeds will support clinical development and general corporate purposes.
Why It Matters
Protara's $75 million stock offering signifies funding for clinical programs, potentially advancing its pipeline and impacting future revenue, thus influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Protara Therapeutics (TARA) reported updated interim results for its Phase II ADVANCE-2 trial of TARA-002, targeting BCG-naive non-muscle invasive bladder cancer patients.
Why It Matters
Protara's updated interim results for TARA-002 could indicate the treatment's efficacy, impacting stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Protara Therapeutics reported TARA-002 has a 72% complete response rate in BCG-Naïve patients. Favorable safety noted, with no severe adverse events. Interim results from ADVANCED-2 trial expected Q1 2026.
Why It Matters
TARA-002 shows strong response rates in BCG-Naïve patients and favorable safety, indicating potential FDA approval and market viability, which could drive stock performance for Protara Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Protara Announces Proposed Public Offering
1 month ago
Quick Summary
Protara Therapeutics (Nasdaq: TARA) has launched a $75 million public offering of common stock and pre-funded warrants to fund clinical development and general corporate purposes.
Why It Matters
Protara Therapeutics' $75 million public offering signals capital raising for clinical development, impacting share dilution and future growth potential, crucial for investors' assessments of risk and reward.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TARA Stock
What is Protara Therapeutics Inc.'s (TARA) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Protara Therapeutics Inc. (TARA) has a median price target of $24.50. The highest price target is $30.00 and the lowest is $21.00.
Is TARA stock a good investment in 2026?
According to current analyst ratings, TARA has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TARA stock?
Wall Street analysts predict TARA stock could reach $24.50 in the next 12 months. This represents a 367.6% increase from the current price of $5.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Protara Therapeutics Inc.'s business model?
Protara Therapeutics focuses on developing innovative treatments for rare diseases and conditions with unmet medical needs. The company generates revenue primarily through the advancement of its drug candidates, such as TARA-002, which is in development for lymphatic malformations and bladder cancer.
What is the highest forecasted price for TARA Protara Therapeutics Inc.?
The highest price target for TARA is $30.00 from Leland Gershell at Oppenheimer, which represents a 472.5% increase from the current price of $5.24.
What is the lowest forecasted price for TARA Protara Therapeutics Inc.?
The lowest price target for TARA is $21.00 from Soumit Roy at Jones Trading, which represents a 300.8% increase from the current price of $5.24.
What is the overall TARA consensus from analysts for Protara Therapeutics Inc.?
The overall analyst consensus for TARA is bullish. Out of 11 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $24.50.
How accurate are TARA stock price projections?
Stock price projections, including those for Protara Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 7:32 AM UTC